Is it a Good Idea to Invest in Immunocore Stock Right Now?

Immunocore IMCR is witnessing a strong sales uptake for its sole marketed drug, Kimmtrak (tebentafusp-tebn), which is approved for treating patients with unresectable or metastatic uveal melanoma (mUM).

Kimmtrak is approved in 39 countries, including the United States, the European Union, Canada, and others. The product has been launched in 26 countries worldwide and continues to be the standard of care for mUM in most markets where it has been launched.

Kimmtrak generated sales worth $310 million in 2024, up almost 30% year over year. Kimmtrak sales were driven by increased volume in the United States and expansion into other countries worldwide. In the first quarter of 2025, sales of the drug rose 33.6% on a year-over-year basis to $93.9 million.

IMCR Stock Performance

Year to date, shares of Immunocore have risen 5.8% against the industry’s decline of 5.5%.

IMCR's Label Expansion Studies on Kimmtrak & Other Activities

Several label expansion studies evaluating Kimmtrak both as monotherapy and in combination with other therapies are currently ongoing, targeting an earlier-line setting for melanoma indications.

The company aims to reach more mUM patients with Kimmtrak worldwide in 2025 through additional launches and increased community penetration.

Immunocore is developing its pipeline candidate, brenetafusp, in combination with Bristol Myers’ BMY blockbuster cancer drug, Opdivo (nivolumab), in a phase III study for treating first-line advanced cutaneous melanoma.

The candidate is also being investigated in early-to-mid-stage studies both as monotherapy and as combination therapy across multiple tumor types, including ovarian cancer and non-small cell lung cancer (NSCLC).

Opdivo, a key growth driver for BMY, is already approved for various oncology indications. BMY recorded $2.26 billion in Opdivo sales in the first quarter of 2025.

With a strong cash position and some clinical milestones expected later this year, investor focus remains on IMCR stock.

IMCR’s Strong Rank & Rising Estimates

Immunocore has a Zacks Rank #1 (Strong Buy). In the past 30 days, estimates for IMCR’s 2025 loss per share have narrowed from $1.50 to 86 cents. During the same time, loss per share estimates for 2026 have narrowed from $1.68 to $1.34.

Immunocore Holdings PLC Sponsored ADR Price and Consensus

Immunocore Holdings PLC Sponsored ADR price-consensus-chart | Immunocore Holdings PLC Sponsored ADR Quote

Another Stock to Consider

Another drug/biotech stock to consider is CorMedix CRMD, which currently carries a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.

In the past 30 days, 2025 earnings estimates for CorMedix have improved from 72 cents per share to 93 cents per share. CRMD shares have surged 51.3% year to date.

CRMD’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 25.82%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research